• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性骨髓瘤患者静脉血栓栓塞风险预测列线图的开发与验证:一项中国单中心队列研究

Development and Validation of a Predictive Nomogram for Venous Thromboembolism Risk in Multiple Myeloma Patients: A Single-Center Cohort Study in China.

作者信息

Zhang Haolin, Zhang Xi, Li Xiaosheng, Xu Qianjie, Yuan Yuliang, Hu Zuhai, Zhao Yulan, Liu Yao, Zhang Yunyun, Lei Haike

机构信息

Chongqing Cancer Multi-Omics Big Data Application Engineering Research Center, Chongqing University Cancer Hospital, Chongqing 400030, China.

Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing 400030, China.

出版信息

Biomedicines. 2025 Mar 21;13(4):770. doi: 10.3390/biomedicines13040770.

DOI:10.3390/biomedicines13040770
PMID:40299376
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12025081/
Abstract

Venous thromboembolism (VTE) is a significant complication in patients with multiple myeloma (MM) that adversely affects morbidity, mortality, and treatment outcomes. This study aimed to develop and validate a predictive nomogram for assessing VTE risk in MM patients using clinicopathological factors. Clinical data, including 25 candidate risk factors, were collected. Univariate and multivariate logistic regression analyses were performed to identify independent risk factors for VTE. The nomogram was constructed using these variables, and its performance was evaluated by plotting receiver operating characteristic (ROC) curves, calculating the area under the curve (AUC), and conducting calibration and decision curve analysis (DCA). Additionally, an online calculator was developed for clinical use. In total, 148 patients (17.5%) developed VTE in this study. The independent risk factors included age, Karnofsky performance status (KPS), anticoagulation therapy, erythropoietin use, and hemoglobin (Hb), platelet (PLT), calcium (Ca), activated partial thromboplastin time (APTT), and D-dimer levels. The nomogram demonstrated robust discriminative ability, with a C-index of 0.811 in the training cohort and 0.714 in the validation cohort. The calibration curves exhibited a high level of agreement between the predicted and observed probabilities. DCA confirmed the nomogram's clinical utility across various threshold ranges, outperforming the "treat all" and "treat none" strategies. This study successfully developed and validated a nomogram for predicting VTE risk in MM patients, demonstrating substantial predictive accuracy and clinical applicability. The nomogram and accompanying online calculator provide valuable tools for individualized VTE risk assessment and informed clinical decision-making.

摘要

静脉血栓栓塞症(VTE)是多发性骨髓瘤(MM)患者的一种严重并发症,会对发病率、死亡率及治疗结果产生不利影响。本研究旨在利用临床病理因素开发并验证一种用于评估MM患者VTE风险的预测列线图。收集了包括25个候选风险因素在内的临床数据。进行单因素和多因素逻辑回归分析以确定VTE的独立风险因素。使用这些变量构建列线图,并通过绘制受试者操作特征(ROC)曲线、计算曲线下面积(AUC)以及进行校准和决策曲线分析(DCA)来评估其性能。此外,还开发了一个供临床使用的在线计算器。在本研究中,共有148例患者(17.5%)发生了VTE。独立风险因素包括年龄、卡氏功能状态(KPS)、抗凝治疗、促红细胞生成素使用情况以及血红蛋白(Hb)、血小板(PLT)、钙(Ca)、活化部分凝血活酶时间(APTT)和D-二聚体水平。该列线图显示出强大的判别能力,在训练队列中的C指数为0.811,在验证队列中的C指数为0.714。校准曲线显示预测概率与观察概率之间具有高度一致性。DCA证实了该列线图在各种阈值范围内的临床实用性,优于“全部治疗”和“不治疗”策略。本研究成功开发并验证了一种用于预测MM患者VTE风险的列线图,显示出较高的预测准确性和临床适用性。该列线图及配套的在线计算器为个性化VTE风险评估和明智的临床决策提供了有价值的工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/063d/12025081/f863e5000299/biomedicines-13-00770-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/063d/12025081/e5535e22d387/biomedicines-13-00770-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/063d/12025081/0ed2d2b33d30/biomedicines-13-00770-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/063d/12025081/d98f7775d419/biomedicines-13-00770-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/063d/12025081/f863e5000299/biomedicines-13-00770-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/063d/12025081/e5535e22d387/biomedicines-13-00770-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/063d/12025081/0ed2d2b33d30/biomedicines-13-00770-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/063d/12025081/d98f7775d419/biomedicines-13-00770-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/063d/12025081/f863e5000299/biomedicines-13-00770-g004.jpg

相似文献

1
Development and Validation of a Predictive Nomogram for Venous Thromboembolism Risk in Multiple Myeloma Patients: A Single-Center Cohort Study in China.多发性骨髓瘤患者静脉血栓栓塞风险预测列线图的开发与验证:一项中国单中心队列研究
Biomedicines. 2025 Mar 21;13(4):770. doi: 10.3390/biomedicines13040770.
2
Derivation, validation and assessment of a novel nomogram-based risk assessment model for venous thromboembolism in hospitalized patients with lung cancer: A retrospective case control study.基于列线图的肺癌住院患者静脉血栓栓塞症新型风险评估模型的推导、验证与评估:一项回顾性病例对照研究
Front Oncol. 2022 Oct 10;12:988287. doi: 10.3389/fonc.2022.988287. eCollection 2022.
3
A nomogram model based on the systemic immune-inflammation index to predict the risk of venous thromboembolism in elderly patients after hip fracture: A retrospective cohort study.基于全身免疫炎症指数的列线图模型预测老年髋部骨折患者静脉血栓栓塞风险:一项回顾性队列研究。
Heliyon. 2024 Mar 20;10(6):e28389. doi: 10.1016/j.heliyon.2024.e28389. eCollection 2024 Mar 30.
4
Development and validation of a nomogram model for predicting venous thromboembolism risk in lung cancer patients treated with immune checkpoint inhibitors: A cohort study in China.开发并验证一种列线图模型,用于预测接受免疫检查点抑制剂治疗的肺癌患者发生静脉血栓栓塞风险:中国的一项队列研究。
Cancer Med. 2024 Aug;13(16):e70115. doi: 10.1002/cam4.70115.
5
Development and validation of a nomogram for predicting venous thromboembolism risk in post-surgery patients with cervical cancer.预测宫颈癌术后患者静脉血栓栓塞风险的列线图的开发与验证
World J Surg Oncol. 2024 Dec 31;22(1):354. doi: 10.1186/s12957-024-03649-2.
6
Development and validation of a nomogram to assess postoperative venous thromboembolism risk in patients with stage IA non-small cell lung cancer.制定并验证了一个列线图模型,用于评估 IA 期非小细胞肺癌患者术后静脉血栓栓塞风险。
Cancer Med. 2023 Jan;12(2):1217-1227. doi: 10.1002/cam4.4982. Epub 2022 Jun 27.
7
A novel web-based risk calculator for predicting surgical site infection in HIV-positive facture patients: a multicenter cohort study in China.一种新型基于网络的风险计算器,用于预测 HIV 阳性骨折患者的手术部位感染:中国多中心队列研究。
Front Cell Infect Microbiol. 2024 Jun 26;14:1408388. doi: 10.3389/fcimb.2024.1408388. eCollection 2024.
8
Nomogram for Risk of Secondary Venous Thromboembolism in Stroke Patients: A Study Based on the MIMIC-IV Database.基于 MIMIC-IV 数据库的脑卒中患者继发静脉血栓栓塞风险的列线图研究。
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241254104. doi: 10.1177/10760296241254104.
9
Development and validation of a predictive risk tool for VTE in women with breast cancer under chemotherapy: a cohort study in China.化疗期间乳腺癌女性静脉血栓栓塞症预测风险工具的开发与验证:一项中国队列研究
Breast Cancer. 2025 Jan;32(1):154-165. doi: 10.1007/s12282-024-01646-7. Epub 2024 Nov 16.
10
Nomogram prediction for the risk of venous thromboembolism in patients with lung cancer.肺癌患者静脉血栓栓塞风险的列线图预测
Cancer Cell Int. 2023 Mar 5;23(1):40. doi: 10.1186/s12935-023-02882-1.

本文引用的文献

1
Venous Thromboembolism in Patients with Neuroendocrine Neoplasms: A Systematic Review of Incidence, Types, and Clinical Outcomes.神经内分泌肿瘤患者的静脉血栓栓塞:发病率、类型及临床结局的系统评价
Cancers (Basel). 2025 Jan 10;17(2):212. doi: 10.3390/cancers17020212.
2
The Risk of Venous Thromboembolism and Ischemic Stroke Stratified by VTE Risk Following Multiple Myeloma: A Korean Population-Based Cohort Study.多发性骨髓瘤后静脉血栓栓塞风险分层的静脉血栓栓塞和缺血性卒中风险:一项基于韩国人群的队列研究
J Clin Med. 2024 May 11;13(10):2829. doi: 10.3390/jcm13102829.
3
A nomogram to predict the risk of venous thromboembolism in patients with colon cancer in China.
用于预测中国结肠癌患者静脉血栓栓塞风险的列线图。
Cancer Med. 2024 May;13(9):e7231. doi: 10.1002/cam4.7231.
4
Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines.多发性骨髓瘤的血栓预防:基于病例的综述及实用指南。
Ann Hematol. 2024 Oct;103(10):3881-3888. doi: 10.1007/s00277-024-05733-9. Epub 2024 Apr 17.
5
Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysis.来那度胺和地塞米松联合卡非佐米或硼替佐米治疗初诊多发性骨髓瘤的血栓栓塞风险:一项比较系统评价和荟萃分析。
Am J Hematol. 2024 Jun;99(6):1056-1065. doi: 10.1002/ajh.27288. Epub 2024 Mar 15.
6
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in Chinese patients with multiple myeloma: A single-center retrospective cohort study.IMPEDE VTE 评分在中国多发性骨髓瘤患者静脉血栓栓塞预测中的验证:一项单中心回顾性队列研究。
Thromb Res. 2024 Apr;236:130-135. doi: 10.1016/j.thromres.2024.02.011. Epub 2024 Feb 15.
7
D-dimer predicts venous thromboembolism in multiple myeloma: a nested case-control study.D-二聚体预测多发性骨髓瘤患者的静脉血栓栓塞:一项巢式病例对照研究。
Res Pract Thromb Haemost. 2023 Oct 19;7(8):102235. doi: 10.1016/j.rpth.2023.102235. eCollection 2023 Nov.
8
Development and validation of a nomogram model for predicting the risk of venous thromboembolism in lymphoma patients undergoing chemotherapy: a prospective cohort study conducted in China.在中国开展的前瞻性队列研究:开发和验证用于预测化疗淋巴瘤患者静脉血栓栓塞风险的列线图模型。
Ann Med. 2023;55(2):2275665. doi: 10.1080/07853890.2023.2275665. Epub 2023 Dec 22.
9
Development and Validation of a Prediction Model for Venous Thrombus Embolism (VTE) in Patients With Colorectal Cancer.开发和验证用于预测结直肠癌患者静脉血栓栓塞症(VTE)的模型。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231186790. doi: 10.1177/15330338231186790.
10
Hematologists' awareness of venous thromboembolism in multiple myeloma: a national survey in China.中国血液病学家对多发性骨髓瘤静脉血栓栓塞症的认知:一项全国性调查。
Ann Med. 2023;55(2):2263019. doi: 10.1080/07853890.2023.2263019. Epub 2023 Nov 20.